Key facts
- It has raised $6.0M; the latest was Early Stage VC ($6.0M) in Mar 2026.
- Notable investors include MassChallenge, Pioneer Fund, SOSV, Capital Factory, StartX (US) — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Surf Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Surf Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Surf Therapeutics
Developer of neuromodulatory technology designed for the treatment of autoimmune disorders. The company's technology offers treatment for chronic inflammatory autoimmune disorders without using drugs by using the body's natural anti-inflammatory pathway to restore immune balance, enabling patients to get healthy, balanced, and free from the constraints of pharmaceutical-dependent treatments.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2022
- Employees
- 10
- Website
- surftherapeutics.com/
- Ownership
- Privately Held (backing)
Surf Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Surf Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Surf Therapeutics in its N-PORT filings yet. We sweep new filings monthly.